264 related articles for article (PubMed ID: 29970892)
1. PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer.
Wang Q; Shi YL; Zhou K; Wang LL; Yan ZX; Liu YL; Xu LL; Zhao SW; Chu HL; Shi TT; Ma QH; Bi J
Cell Death Dis; 2018 Jul; 9(7):739. PubMed ID: 29970892
[TBL] [Abstract][Full Text] [Related]
2. Chemosensitization of HT29 and HT29-5FU Cell Lines by a Combination of a Multi-Tyrosine Kinase Inhibitor and 5FU Downregulates ABCC1 and Inhibits PIK3CA in Light of Their Importance in Saudi Colorectal Cancer.
Abdalla AN; Malki WH; Qattan A; Shahid I; Hossain MA; Ahmed M
Molecules; 2021 Jan; 26(2):. PubMed ID: 33440689
[TBL] [Abstract][Full Text] [Related]
3. Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway.
Chen Z; Wang C; Dong H; Wang X; Gao F; Zhang S; Zhang X
Mol Med; 2020 Jan; 26(1):14. PubMed ID: 32000660
[TBL] [Abstract][Full Text] [Related]
4.
Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
[TBL] [Abstract][Full Text] [Related]
5. Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
Park YL; Kim HP; Cho YW; Min DW; Cheon SK; Lim YJ; Song SH; Kim SJ; Han SW; Park KJ; Kim TY
Int J Cancer; 2019 Jan; 144(2):389-401. PubMed ID: 29978469
[TBL] [Abstract][Full Text] [Related]
6. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of Lgr5 correlates with resistance to 5-FU-based chemotherapy in colorectal cancer.
Hsu HC; Liu YS; Tseng KC; Hsu CL; Liang Y; Yang TS; Chen JS; Tang RP; Chen SJ; Chen HC
Int J Colorectal Dis; 2013 Nov; 28(11):1535-46. PubMed ID: 23784051
[TBL] [Abstract][Full Text] [Related]
8. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
[TBL] [Abstract][Full Text] [Related]
9. Fisetin and 5-fluorouracil: Effective combination for PIK3CA-mutant colorectal cancer.
Khan N; Jajeh F; Eberhardt EL; Miller DD; Albrecht DM; Van Doorn R; Hruby MD; Maresh ME; Clipson L; Mukhtar H; Halberg RB
Int J Cancer; 2019 Dec; 145(11):3022-3032. PubMed ID: 31018249
[TBL] [Abstract][Full Text] [Related]
10. PI3K expression and PIK3CA mutations are related to colorectal cancer metastases.
Zhu YF; Yu BH; Li DL; Ke HL; Guo XZ; Xiao XY
World J Gastroenterol; 2012 Jul; 18(28):3745-51. PubMed ID: 22851869
[TBL] [Abstract][Full Text] [Related]
11. Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
Lee DW; Han SW; Cha Y; Bae JM; Kim HP; Lyu J; Han H; Kim H; Jang H; Bang D; Huh I; Park T; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY
Cancer; 2017 Sep; 123(18):3513-3523. PubMed ID: 28513830
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.
Domingo E; Church DN; Sieber O; Ramamoorthy R; Yanagisawa Y; Johnstone E; Davidson B; Kerr DJ; Tomlinson IP; Midgley R
J Clin Oncol; 2013 Dec; 31(34):4297-305. PubMed ID: 24062397
[TBL] [Abstract][Full Text] [Related]
13. Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis.
Mei ZB; Duan CY; Li CB; Cui L; Ogino S
Ann Oncol; 2016 Oct; 27(10):1836-48. PubMed ID: 27436848
[TBL] [Abstract][Full Text] [Related]
14. Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.
Fernandes MS; Melo S; Velho S; Carneiro P; Carneiro F; Seruca R
Oncotarget; 2016 Oct; 7(42):68546-68558. PubMed ID: 27602501
[TBL] [Abstract][Full Text] [Related]
15. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
[TBL] [Abstract][Full Text] [Related]
17. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.
Kim A; Lee JE; Lee SS; Kim C; Lee SJ; Jang WS; Park S
Int J Cancer; 2013 Aug; 133(4):984-96. PubMed ID: 23475782
[TBL] [Abstract][Full Text] [Related]
18. PIK3CA mutation affects the proliferation of colorectal cancer cells through the PI3K-MEK/PDK1-GPT2 pathway.
Chen W; Dai G; Qian Y; Wen L; He X; Liu H; Gao Y; Tang X; Dong B
Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34751411
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer.
Hao Y; Samuels Y; Li Q; Krokowski D; Guan BJ; Wang C; Jin Z; Dong B; Cao B; Feng X; Xiang M; Xu C; Fink S; Meropol NJ; Xu Y; Conlon RA; Markowitz S; Kinzler KW; Velculescu VE; Brunengraber H; Willis JE; LaFramboise T; Hatzoglou M; Zhang GF; Vogelstein B; Wang Z
Nat Commun; 2016 Jun; 7():11971. PubMed ID: 27321283
[TBL] [Abstract][Full Text] [Related]
20. Co-expression of Lgr5 and CXCR4 characterizes cancer stem-like cells of colorectal cancer.
Wu W; Cao J; Ji Z; Wang J; Jiang T; Ding H
Oncotarget; 2016 Dec; 7(49):81144-81155. PubMed ID: 27835894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
